Panagora Asset Management’s ADC Therapeutics ADCT Stock Holding History

Panagora Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$613K	Sell	572,816 -118,459	-17%	-$346K	﹤0.01%	848
2026 Q1	$2.59M	Buy	691,275 +97,019	+16%	+$382K	0.01%	538
2025 Q4	$2.1M	Buy	594,256 +49,995	+9%	+$203K	0.01%	559
2025 Q3	$2.18M	Buy	544,261 +272,902	+101%	+$860K	0.01%	510
2025 Q2	$727K	Buy	271,359 +217,173	+401%	+$457K	﹤0.01%	710
2025 Q1	$76.4K	Buy	+54,186	New	+$92.1K	﹤0.01%	1085

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Panagora Asset Management's ADCT Position: Q2 2026 in Review

Panagora Asset Management reduced its ADC Therapeutics (ADCT) stake by 17% in Q2 2026, selling an estimated $346K and leaving 572,816 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #848.

Panagora Asset Management first reported a position in ADCT in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.59M in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Panagora Asset Management held 572,816 shares of ADC Therapeutics worth $613K as of Q2 2026.
Panagora Asset Management sold 118,459 ADC Therapeutics shares in Q2 2026, an estimated $346K.
ADC Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #848 holding.
Panagora Asset Management first reported a position in ADC Therapeutics in Q1 2025 and has held it in 6 quarters since.
Panagora Asset Management's ADC Therapeutics position peaked at $2.59M in Q1 2026.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.